Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation

New England Journal of Medicine

Volumn 377, Issue 5, 2017, Pages 454-464

  Stone, R M ^a   Mandrekar, S J ^b,c   Sanford, B L ^d   Laumann, K ^b,c   Geyer, S ^c,e   Bloomfield, C D ^e   Thiede, C ^f   Prior, T W ^e   Dohner, K ^g   Marcucci, G ^e   Lo Coco, F ^k   Klisovic, R B ^e   Wei, A ^l   Sierra, J ^m   Sanz, M A ⁿ   Brandwein, J M ^o   De Witte, T ^p   Niederwieser, D ^h   Appelbaum, F R ^q   Medeiros, B C ^r   Tallman, M S ^s   Krauter, J ⁱ   Schlenk, R F ^g   Ganser, A ⁱ   Serve, H ^j   Ehninger, G ^f   Amadori, S ^k   Larson, R A ^t   Dohner, H ^g   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Divisions of Biomedical Statistics and Informatics   (United States)

^c MAYO CLINIC   (United States)

^d DUKE UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^k UNIVERSITY OF ROME TOR VERGATA   (Italy)

^l ALFRED HOSPITAL   (Australia)

^m UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^o PRINCESS MARGARET HOSPITAL   (Canada)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^q Fred Hutchinson Cancer Research Center   (United States)

^r STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^t UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; MIDOSTAURIN; PLACEBO; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; FLT3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; STAUROSPORINE;

ACUTE MYELOID LEUKEMIA; ADULT; AGE; ALLELE; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; BLOOD CELL COUNT; BONE MARROW DISEASE; BONE MARROW HYPOCELLULARITY; CAUSE OF DEATH; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETICS; DESQUAMATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLT3 GENE; GENE MUTATION; HAZARD RATIO; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; INTERNAL TANDEM DUPLICATION; LEUKEMIA REMISSION; LEUKOPENIA; LUNG INFILTRATE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POINT MUTATION; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; STAUROSPORINE; YOUNG ADULT;

EID: 85025432950     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1614359     Document Type: Article

References (29)

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373: 1136-52.
2. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-65.
3. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-74.
4. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-74.
5. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733-9.
6. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-89.
7. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374: 2209-21.
8. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-18.
9. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116: 5089-102.
10. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-9.
11. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-Type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 2001; 61: 7233-9.
12. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-Activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-35.
13. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007; 110: 1262-70.
14. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008; 111: 1552-9.
15. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002; 99: 310-8.
16. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1: 433-43.
17. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54-60.
18. Smith BD, Levis M, Beran M, et al. Single-Agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669-76.
19. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013; 31: 3681-7.
20. Perl AE, Altman JK, Cortes JE, et al. Final results of the Chrysalis trial: A firstin-human phase 1/2 dose-escalation, dose-expansion study of gilteritinib in patients with relapsed/refractory acute myeloid leukemia. Blood 2016; 128: 1069. abstract.
21. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485-92.
22. Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012; 26: 2061-8.
23. Fischer T, Stone RM, DeAngelo DJ, et al. Phase IIB trial of oral midostaurin, the FMS-like tyrosine kinase receptor and multi-Targeted inhibitor in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wildtype or mutated FLT3. J Clin Oncol 2010; 28: 4339-45.
24. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016; 374: 2530-41.
25. Röllig C, Serve H, Höttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial. Lancet Oncol 2015; 16: 1691-9.
26. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 2015; 126: 319-27.
27. Chen YB, Li S, Lane AA, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 2014; 20: 2042-8.
28. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113: 6567-71.
29. Schlenk R, Dohner K, Salih H, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose cytarabine. Blood 2015; 126: 322.